Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?

European Journal of Nuclear Medicine

Volumn 26, Issue 1, 1999, Pages 8-11

  Buffaz, Pierre Denis ^a   Gauchez, Anne Sophie ^a   Caravel, Jean Pierre ^a   Vuillez, Jean Philippe ^a   Cura, Christophe ^a   Agnius Delord, Claudine ^a   Fagret, Daniel ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bone scan; Breast cancer; Lung cancer; Tumour markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; MEDRONATE TECHNETIUM TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0033016509     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050352     Document Type: Article

References (21)

1. 1. Lund F, Smith PH, Sucius S and EORTC Urological Group. Do bone scans predict prognosis in prostatic cancer? Br J Urol 1984; 56: 58-63.
2. 2. George NJR. Natural history of localized prostatic cancer managed by conservative therapy alone. Lancet 1988; I: 494-496.
3. 3. Lentle BC, McGowan DG, Dierich H. Technetium-99m polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 1974; 46: 543-548.
4. 4. O'Donoghue EPN, Constable ER, Sherwood T, Stevenson JJ, Chrisholm GD. Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 1978; 50: 172-177.
5. 5. Bishop HM, Blamey RW, Morris AH, Rose DH, Preston B, Lane J, Doyle PJ. Bone scanning: its lack of value in the follow-up of patients with breast cancer. Br J Surg 1979; 66: 752-754.
6. 6. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am 1993; 20: 705-711.
7. 7. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994; 17: 432-436.
8. 8. Freitas JE, Gilvydas R, Ferry JD, Gonzalez JA. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. J Nucl Med 1991; 32: 1387-1390.
9. 9. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, Ciardi L, Sacchetti GM, Inglese E. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-211.
10. 10. Terris MK, Klonecke AS, Ross McDougall I, Stamey TA. Utilization of bone scans in conjunction with prostate-specific antigen levels in the recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 1991; 32: 1713-1717.
11. 11. O'Donoghue JM, Rogers E, Grimes H, McCarthy P, Corcoran M, Bredin H, Given HF. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiol 1993; 66: 672-676.
12. 12. Oommen R, Geethanjali FS, Gopalakrishnan G, Chacko N, John S, Kanagasabapathy AS, Roul RK. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma of prostate. Br J Radiol 1994; 67: 469-471.
13. 13. Sissons GRJ, Clements R, Peeling WB, Penney MD. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer? Br J Radiol 1992; 65: 861-864.
14. 14. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997; 76: 760-764.
15. 15. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-2877.
16. 16. Antoine E, Kayitalire L, Spielmann M. CA15-3 et cancer du sein. Rev Med Interne 1994; 15: 650-662.
17. 17. Wickerham L, Fisher B, Cronin W, and members of the NSABP Committee for Treatment Failure Criteria. Stolbach L, Abramson N, Bowman D, Decker PJ, Eisenberg P, Foster R, Glass A, Kay S, Kyle A, Prager D, Pritchard K. The efficacity of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat 1984; 4: 303-307.
18. 18. Pedrazzini A, Gelber R, Isley M, Castiglione M, Goldhirsch A. First repeated bone scan in the observation of patients with operable breast cancer, J Clin Oncol 1986; 4: 389-394.
19. 19. Tomlinson IPM, Whyman A, Barrett JA, Kremer JK. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur J Cancer 1995; 31: 899-902.
20. 20. Safi F, Kohler I, Röttinger E, Beger H. The value of the tumor marker CA15-3 in diagnosing and monitoring breast cancer. Cancer 1991; 68: 574-582.
21. 21. Pantelides ML, Bowman SP, George JR. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299-303.